Sunovion to buy Elevation Pharmaceuticals in a deal with a $100m upfront payment

Sunovion Pharmaceuticals Inc., the Marlborough subsidiary of a Japanese drug company, has agreed to buy Elevation­ Pharmaceuticals Inc., a privately held company specializing in the development of aerosol therapies for patients with respiratory diseases.

Sunovion will make an upfront payment of $100 million to shareholders of California-based Elevation when the deal closes. The agreement also calls for milestone payments of up to $90 million if an Elevation Pharmaceuticals drug candidate achieves certain goals. If the drug candidate gets regulatory approval, Sunovion said it could make commercial milestone payments of up to $210 million. Subsequent payments up to $30 million could occur.


An Elevation drug candidate referenced in the sales agreement is EP-101, a potential treatment for chronic obstructive pulmonary disease.

Sunovion, formerly Sepracor, was bought by Dainippon Sumitomo Pharma in 2009.

Chris Reidy

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.